ホーム › 乳がん › ニューメキシコ › Albuquerque
Albuquerque、NMにおける乳がんの臨床試験
Albuquerqueとその周辺地域（約30マイル以内）の拠点で、乳がんに関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Presbyterian Medical Group, Albuquerque
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- 他1件
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- The University of New Mexico, Albuquerque
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
被験者募集中第3相
- Presbyterian Kaseman Hospital ( Site 0072), Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0047), Albuquerque
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Albuquerque
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- 他1件
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- New Mexico Oncology & Hematology Consultants, Albuquerque
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Exigent Research LLC/New Mexico Oncology Hematology Consultants Ltd., Albuquerque
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Albuquerque
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
被験者募集中第3相
- Presbyterian Kaseman Hospital, Albuquerque
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- University of New Mexico Cancer Center, Albuquerque
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
被験者募集中
- University of New Mexico, Albuquerque
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- 他1件
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Albuquerque
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
被験者募集中第3相
- University of New Mexico Cancer Center, Albuquerque
BostonGene and Exigent Genomic INsight Study
被験者募集中観察研究
- New Mexico Cancer Center, Albuquerque
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Albuquerqueにおける他の研究
- 非小細胞肺癌18件の研究
- 卵巣がん15件の研究
- がん（全種類）14件の研究
- 肺がん14件の研究
- 転移性癌12件の研究
- 子宮内膜がん12件の研究
- 2型糖尿病11件の研究
- 心血管疾患10件の研究
- 悪性黒色腫9件の研究
- 急性骨髄性白血病9件の研究
- 前立腺がん9件の研究
- 慢性腎臓病8件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。